Skip to main content
Clinical Trials/NCT06336668
NCT06336668
Not yet recruiting
Not Applicable

Source of Human Milk Fortifier and Intestinal Oxygenation in Preterm Infants <30 Weeks Gestation

University of Calgary0 sites18 target enrollmentJune 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Feeding; Difficult, Newborn
Sponsor
University of Calgary
Enrollment
18
Primary Endpoint
Change in Splanchnic regional oxygenation(rSO2S) measured by Near Infrared Spectroscopy
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

Preterm infants require higher nutritional intakes during the neonatal phase than they do at any other stage of their development. Standard volumes of human milk alone do not offer sufficient nourishment to these infants. There are multiple options for fortifying human milk, which vary depending on whether the fortifier is derived from bovine sources (B-HMF) or human sources (H-HMF). Fortifying human milk has been proven to enhance growth in preterm infants without raising the risk of necrotizing enterocolitis (NEC), though it could potentially affect feeding tolerance. Changes in blood flow and oxygen levels in the intestines are commonly observed in infants experiencing feeding intolerance. Research indicates that feeding a mother's own milk (MOM) doesn't affect splanchnic (intestinal) oxygenation, whereas it decreases when feeding bovine-derived human milk fortifiers (B-HMF) or preterm formula, indicating greater oxygen requirements in the intestines of preterm infants fed these alternatives.

The goal of this clinical trial is to compare the effect of H-HMF and B-HMF on splanchnic oxygenation in infants less than 30 weeks.

Detailed Description

The fortification of human milk has been proven to enhance growth without raising the risk of necrotizing enterocolitis, although it may affect feeding tolerance. Non-invasive techniques like Doppler ultrasonography of the superior mesenteric artery (SMA) and near-infrared spectroscopy (NIRS) have been utilized to evaluate mesenteric blood flow and intestinal oxygenation in preterm infants. Numerous studies have investigated the relationship between SMA flow and feeding intolerance. Findings indicate a significant correlation between increased mean Superior Mesenteric Artery blood flow velocity and early tolerance of enteral feeding. Moreover, research suggests a higher incidence of necrotizing enterocolitis (NEC) in preterm infants exhibiting increased resistance patterns of SMA blood flow velocity on the first day. Non-invasive monitoring methods offer the ability to assess the impact of various fortification products on intestinal perfusion and oxygenation. This could aid in determining the most suitable fortification product to minimize episodes of feeding intolerance.

Registry
clinicaltrials.gov
Start Date
June 1, 2024
End Date
February 28, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Belal Alshaikh

Principal Investigator

University of Calgary

Eligibility Criteria

Inclusion Criteria

  • Preterm infants born \<30 weeks' gestation age and less than 1500g of weight.
  • Admitted in Neonatal Intensive Care Unit at Foothills Medical Center
  • Reached full fortified enteral feed and at least 21 days of chronological age.

Exclusion Criteria

  • Chromosomal or major congenital anomalies
  • Infants diagnosed with NEC.

Outcomes

Primary Outcomes

Change in Splanchnic regional oxygenation(rSO2S) measured by Near Infrared Spectroscopy

Time Frame: 6 hours

Measurements of Near Infrared Spectroscopy are continuous but readings of interest are: before feeding, 30 and 120 minutes after finishing feed.

Secondary Outcomes

  • Changes in SMA doppler end-diastolic velocity (EDV)(6 hours)
  • Changes in SMA doppler peak flow velocity (PSV)(6 hours)
  • Changes in SMA doppler Porcelout's resistance index (RI)(6 hours)

Similar Trials